3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
103
Recruiting
59
Unknown
53
Terminated
19
Not yet recruiting
18
Active not recruiting
12
Withdrawn
9
Suspended
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Specimen Handling
29
Magnetic Resonance Spectroscopy
18
Biopsy
16
Cyclophosphamide
15
Nivolumab
10
Paclitaxel
9
Vincristine
8
Cisplatin
8
venetoclax
7
Prednisone
7
Gemcitabine
7
Doxorubicin
7
Bevacizumab
7
Azacitidine
7
pembrolizumab
6
Radiotherapy
6
Fluorouracil
6
Etoposide
6
Drug Therapy
6
Docetaxel
6
Rituximab
5
Radiosurgery
5
Oxaliplatin
5
Irinotecan
5
Injections
5
Everolimus
5
Capecitabine
5
fludarabine phosphate
4
Taxes
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Interventional
×
Folfox protocol
×
Clear all
NCT05033522
2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3
Suspended
150 enrolled